Program
diacerein
Also written as “Diacerein”, “diacerein 1% ointment” and “AC-201”.
Its studies are mostly in Osteoarthritis, Knee · Epidermolysis Bullosa Simplex · Epidermolysis Bullosa · Psoriasis · Gout, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Castle Creek Pharmaceuticals | 70 open or running | phase 2since May 10, 2017 | May 10, 2017 | none ahead |
| TWi Biotechnology | 61 open or running | phase 3since Sep 12, 2023 | Jan 11, 2011 | none ahead |
| Wockhardt | 30 open or running | phase 4since Feb 26, 2007 | Feb 26, 2007 | none ahead |
| TRB Chemedica | 21 open or running | phase 3since Mar 16, 2020 | Jun 28, 2010 | Dec 31, 2026phase 3 · NCT04318041 |
| Accro Bioscience (Suzhou) | 10 open or running | phase 2since May 7, 2025 | May 7, 2025 | none ahead |
| ANS Pharma | 10 open or running | phase 2since Jun 27, 2017 | Jun 27, 2017 | none ahead |
| TRB Chemedica International | 10 open or running | phase 3since Feb 10, 2016 | Feb 10, 2016 | none ahead |
Also a collaborator on its studies: arthrolab-inc and tkl-research-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Feb 26, 2007.
- Jan 11, 2011TWi Biotechnology's first study: phase 2 study in Diabetes Mellitus, Type 2New to TWi BiotechnologyTWi Biotechnology · NCT01276106 · 259 enrolled · United States, Taiwan
- Oct 19, 2012Phase 2 study in HyperuricemiaTWi Biotechnology · NCT01712204 · 82 enrolled · Taiwan
- Nov 6, 2014Phase 2 study in GoutTWi Biotechnology · NCT02287818 · 127 enrolled · Taiwan
- Feb 10, 2016TRB Chemedica International's first study: phase 3 study in OsteoarthritisNew to TRB Chemedica InternationalTRB Chemedica International · NCT02688400 · 380 enrolled · Austria, Belgium, Canada and more
- May 10, 2017Castle Creek Pharmaceuticals's first study: phase 2 study in Epidermolysis Bullosa SimplexNew to Castle Creek PharmaceuticalsCastle Creek Pharmaceuticals · NCT03154333 · 54 enrolled · United States, Australia, Austria and more
- Jun 27, 2017ANS Pharma's first study: phase 2 study in Diabetes ComplicationsNew to ANS PharmaANS Pharma · NCT03208309 · 40 enrolled · Brazil
- Sep 14, 2017Phase 2 study in Pemphigoid, BullousTWi Biotechnology · NCT03286582 · 10 enrolled · Taiwan
- Dec 19, 2017Phase 2 study in Epidermolysis BullosaCastle Creek Pharmaceuticals · NCT03389308 · 51 enrolled · United States
- Jan 30, 20182 phase 1 studies in HealthyCastle Creek Pharmaceuticals · NCT03472547, NCT03472534
- Mar 5, 20183 phase 1 studiesCastle Creek Pharmaceuticals · NCT03473197, NCT03473184, NCT03472287
- Mar 8, 2018Phase 2 study in Inherited Epidermolysis BullosaTWi Biotechnology · NCT03468322 · 9 enrolled · Taiwan
- Mar 16, 2020Phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041 · 128 enrolled · Thailand
- Sep 12, 2023Phase 3 study in Epidermolysis Bullosa SimplexTWi Biotechnology · NCT06073132 · 80 enrolled · United States, Australia, Austria and more
- May 7, 2025Accro Bioscience (Suzhou)'s first study: phase 2 study in Plaque PsoriasisNew to Accro Bioscience (Suzhou)Accro Bioscience (Suzhou) · NCT06972888 · 145 enrolled · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041
TargetBeta
“AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.”study text, by rule · the study
Other programs on IL1B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutikizumab | AbbVie | phase 3 | 12 |
| arumakimig | Novartis | phase 2 | 7 |
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06972888Plaque Psoriasis · China | 2 | Completed | Accro Bioscience (Suzhou) | Mar 7, 2025 | 145 |
| NCT06073132Epidermolysis Bullosa Simplex · United States, Australia, Austria and more | 3 | Active, not recruiting | TWi Biotechnology | Jun 10, 2026 | 80 |
| NCT04318041Osteoarthritis, Knee · Thailand | 3 | Active, not recruiting | TRB Chemedica | Dec 31, 2026 | 128 |
| NCT03472287Epidermolysis Bullosa · United States | 1 | Completed | Castle Creek Pharmaceuticals | Jan 31, 2019 | 11 |
| NCT03468322Inherited Epidermolysis Bullosa · Taiwan | 2 | Completed | TWi Biotechnology | Apr 9, 2019 | 9 |
| NCT03473197Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Mar 9, 2018 | 61 |
| NCT03473184Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Dec 15, 2017 | 34 |
| NCT03472547Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Mar 3, 2018 | 234 |
| NCT03472534Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Jan 30, 2018 | 46 |
| NCT03389308Epidermolysis Bullosa · United States | 2 | Completed | Castle Creek Pharmaceuticals | Apr 17, 2020 | 51 |
| NCT03286582Pemphigoid, Bullous · Taiwan | 2 | Terminated | TWi Biotechnology | Dec 25, 2018 | 10 |
| NCT03208309Diabetes Complications · Brazil | 2 | Completed | ANS Pharma | Aug 2015 | 40 |
| NCT03154333Epidermolysis Bullosa Simplex · United States, Australia, Austria and more | 2 | Terminated | Castle Creek Pharmaceuticals | Oct 15, 2018 | 54 |
| NCT02688400Osteoarthritis · Austria, Belgium, Canada and more | 3 | Completed | TRB Chemedica International | Jun 26, 2018 | 380 |
| NCT02287818Gout · Taiwan | 2 | Completed | TWi Biotechnology | Oct 27, 2016 | 127 |
| NCT01712204Hyperuricemia · Taiwan | 2 | Completed | TWi Biotechnology | Sep 2013 | 82 |
| NCT01276106Diabetes Mellitus, Type 2 · United States, Taiwan | 2 | Completed | TWi Biotechnology | Feb 2012 | 259 |
| NCT01264211Arthritis, Rheumatoid · Thailand | 2 | Completed | TRB Chemedica | Jun 2012 | 40 |
| NCT00451360Osteoarthritis, Hip · France | 3 | Completed | Wockhardt | 500 | |
| NCT00445276Osteoarthritis, Knee · France | 4 | Completed | Wockhardt | Sep 2006 | 500 |
| NCT00440661Osteoarthritis · Canada | 4 | Completed | Wockhardt | Oct 2008 | 96 |
How it is read
Names in the registry
- “Diacerein”, 4 entries
- “diacerein 1% ointment”, 4 entries
- “AC-201”, 3 entries
- “AC-203”, 2 entries
- “Diacerein 1% ointment”, 2 entries
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 3 studies
- Epidermolysis Bullosa Simplex, 3 studies
- Epidermolysis Bullosa, 2 studies
- Psoriasis, 1 study
- Gout, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.